GlassScriptPhysician profile
Luis R Barreras
NPI 1780676346
$22,771.47
in general payments reported to CMS, 2019-2025
84 companies · $3,370 in 2025
The $3,370 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,430 · 2020: $1,647 · 2021: $3,974 · 2022: $3,226 · 2023: $3,777 · 2024: $4,348 · 2025: $3,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $263 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,065.05 |
| Education | $263.04 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,429.53 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,938.24 | 2019-2025 | Tagrisso, Lynparza, Imfinzi |
| Pfizer INC. | $1,757.51 | 2019-2025 | |
| Janssen Biotech, INC. | $1,457.26 | 2019-2025 | Darzalex, Imbruvica, Erleada |
| Merck Sharp & Dohme LLC | $1,303.06 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Rigel Pharmaceuticals, INC. | $939.79 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| E.R. Squibb & Sons, L.L.C. | $930.26 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Eisai INC. | $800.69 | 2019-2025 | |
| Celgene Corporation | $706.02 | 2019-2025 | Reblozyl, Pomalyst |
| Incyte Corporation | $589.13 | 2020-2025 | Jakafi |
| Genentech USA, INC. | $515.55 | 2019-2025 | Tecentriq, Polivy, Phesgo |
| Astellas Pharma US INC | $495.76 | 2020-2025 | Vyloy, Xtandi, Xospata |
| Abbvie INC. | $459.49 | 2019-2025 | Venclexta |
| Lilly USA, LLC | $452.42 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $433.76 | 2020-2025 | Ojjaara, Jemperli, Zejula |
Show all 83 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $418.26 | 2020-2023 | Tivdak, Adcetris, Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $390.04 | 2019-2025 | |
| Genzyme Corporation | $386.65 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $371.14 | 2019-2025 | Fruzaqla, Alunbrig, Vonvendi |
| Sobi, INC | $359.89 | 2022-2025 | |
| Emd Serono, INC. | $317.85 | 2019-2025 | Bavencio |
| Adaptive Biotechnologies Corporation | $304.34 | 2022-2025 | Clonoseq |
| Jazz Pharmaceuticals INC. | $291.29 | 2020-2025 | Zepzelca |
| Beigene USA, INC. | $280.69 | 2022-2025 | Brukinsa, Tevimbra |
| Amgen INC. | $240.66 | 2019-2023 | Kyprolis, Lumakras |
| Daiichi Sankyo INC. | $236.79 | 2020-2025 | Enhertu, Datroway |
| Array Biopharma INC | $234.28 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Regeneron Healthcare Solutions, INC. | $225.78 | 2023-2025 | Libtayo |
| Dova Pharmaceuticals | $221.82 | 2019-2021 | |
| Pharmacosmos Therapeutics INC. | $212.70 | 2023-2025 | Monoferric |
| Karyopharm Therapeutics INC. | $189.73 | 2020-2025 | Xpovio |
| Puma Biotechnology, INC. | $172.59 | 2021-2025 | |
| Taiho Oncology, INC. | $160.78 | 2019-2025 | |
| Kyowa Kirin, INC. | $152.19 | 2020-2024 | Poteligeo |
| Exelixis INC. | $147.40 | 2021-2025 | Cabometyx |
| Coherus Oncology, INC. | $138.27 | 2020-2024 | |
| Ipsen Biopharmaceuticals, INC | $124.54 | 2019-2025 | Onivyde, Somatuline Depot, Tazverik |
| Servier Pharmaceuticals LLC | $118.46 | 2023-2025 | |
| Legend Biotech USA INC. | $105.44 | 2024-2025 | Carvykti |
| Tempus Ai, INC | $101.56 | 2025 | Xt Cdx |
| Foundation Medicine, INC. | $81.37 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $80.37 | 2023-2025 | Givlaari |
| Blueprint Medicines Corporation | $75.60 | 2024-2025 | Ayvakit |
| Davol INC. | $75.11 | 2025 | Phasix Mesh |
| Deciphera Pharmaceuticals INC. | $68.12 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $67.59 | 2020-2025 | Pyrukynd |
| Stemline Therapeutics INC. | $57.83 | 2025 | Orserdu |
| Janssen Pharmaceuticals, INC | $55.71 | 2019-2024 | Xarelto |
| Medtronic, INC. | $55.64 | 2025 | Intellis Adaptivestim |
| Alexion Pharmaceuticals, INC. | $54.62 | 2024 | Ultomiris |
| Dendreon Pharmaceuticals LLC | $51.20 | 2025 | Provenge |
| Recordati_rare_diseases_inc. | $49.63 | 2024 | Sylvant |
| Apellis Pharmaceuticals, INC. | $46.89 | 2023 | Empaveli |
| Octapharma USA, INC. | $46.18 | 2023-2024 | Octagam Immune Globulin (Human), Panzyga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.50 | 2019-2025 | |
| Adc Therapeutics America, INC. | $44.09 | 2024-2025 | |
| Mirati Therapeutics, INC. | $43.33 | 2023 | Krazati |
| Myriad Genetic Laboratories, INC. | $42.74 | 2022 | |
| Geron Corporation | $40.17 | 2024-2025 | Rytelo |
| Caris Mpi, INC. | $38.16 | 2025 | Mi Cancer Seek |
| Acceleron Pharma, INC. | $37.24 | 2021 | |
| Global Blood Therapeutics, INC. | $34.58 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $32.60 | 2023 | Neupogen, Neulasta, Avastin |
| Beone Medicines USA, INC. | $32.16 | 2025 | Tevimbra |
| Menarini Silicon Biosystems, INC. | $31.25 | 2025 | |
| Springworks Therapeutics, INC. | $26.25 | 2025 | Ogsiveo |
| Aveo Pharmaceuticals, INC. | $25.81 | 2024 | |
| Biocon Biologics INC | $24.11 | 2024 | Ogivri |
| Accord Healthcare, INC. | $23.71 | 2024 | |
| Azurity Pharmaceuticals, INC. | $23.63 | 2024 | Vivimusta |
| Sumitomo Pharma America, INC. | $23.06 | 2024 | Orgovyx |
| Novocure INC. | $22.89 | 2025 | Optune Lua (Novottf-200t) |
| Sun Pharmaceutical Industries INC. | $21.87 | 2025 | |
| Blue Earth Diagnostics | $21.62 | 2024 | |
| Kite Pharma, INC. | $21.35 | 2025 | Yescarta |
| Emmaus Medical, INC. | $21.04 | 2021 | |
| Pharmaand Gmbh | $18.85 | 2025 | Rubraca |
| Teva Pharmaceuticals USA, INC. | $18.19 | 2020 | |
| Gilead Sciences, INC. | $18.08 | 2025 | Trodelvy |
| Tolmar, INC. | $17.77 | 2025 | Eligard, Rubraca |
| Advanced Accelerator Applications | $17.43 | 2019 | |
| Acrotech Biopharma INC. | $17.30 | 2023 | Beleodaq |
| Organon LLC | $9.22 | 2023 | Ontruzant |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$150.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Barreras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.